Stock CPRX CATALYST PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Catalyst Pharmaceuticals, Inc.

Equities

CPRX

US14888U1016

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
14.89 USD +1.43% Intraday chart for Catalyst Pharmaceuticals, Inc. -1.59% -11.42%
Apr. 10 Catalyst Pharmaceuticals Insider Sold Shares Worth $392,000, According to a Recent SEC Filing MT
Apr. 04 Certain Stock Options of Catalyst Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 4-APR-2024. CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 386.4 346.2 698.1 1,936 1,792 1,757 - -
Enterprise Value (EV) 1 291.9 205.9 506.8 1,637 1,655 1,296 1,071 1,757
P/E ratio 12.5 x 4.7 x 18.3 x 24.8 x 26.7 x 13.2 x 9.96 x 8.75 x
Yield - - - - - - - -
Capitalization / Revenue 3.78 x 2.91 x 4.96 x 9.04 x 4.5 x 3.82 x 3.2 x 2.8 x
EV / Revenue 2.85 x 1.73 x 3.6 x 7.64 x 4.15 x 2.81 x 1.95 x 2.8 x
EV / EBITDA - - - - - 6.86 x 4.4 x 6.57 x
EV / FCF 8.44 x 4.57 x 8.54 x 14.1 x 11.5 x 7.67 x 4.89 x 7.17 x
FCF Yield 11.9% 21.9% 11.7% 7.09% 8.67% 13% 20.5% 13.9%
Price to Book 4.54 x 2.09 x 3.53 x 6.9 x 4.93 x - - -
Nbr of stocks (in thousands) 103,047 103,648 103,118 104,071 106,611 118,011 - -
Reference price 2 3.750 3.340 6.770 18.60 16.81 14.89 14.89 14.89
Announcement Date 3/16/20 3/15/21 3/16/22 3/15/23 2/28/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 102.3 119.1 140.8 214.2 398.2 460.5 548.7 627.8
EBITDA 1 - - - - - 188.9 243.7 267.3
EBIT 1 31.82 41.3 52.38 101.8 86.81 179.1 240.5 284.5
Operating Margin 31.11% 34.69% 37.2% 47.54% 21.8% 38.89% 43.83% 45.31%
Earnings before Tax (EBT) 1 33.41 41.89 52.67 104.7 94.51 188.4 251.8 276.2
Net income 1 31.88 74.98 39.48 83.08 71.41 137 185.4 206.6
Net margin 31.16% 62.97% 28.03% 38.79% 17.93% 29.74% 33.8% 32.91%
EPS 2 0.3000 0.7100 0.3700 0.7500 0.6300 1.129 1.495 1.702
Free Cash Flow 1 34.59 45.02 59.35 116 143.4 169 219.2 245
FCF margin 33.81% 37.81% 42.14% 54.16% 36% 36.7% 39.96% 39.02%
FCF Conversion (EBITDA) - - - - - 89.5% 89.97% 91.67%
FCF Conversion (Net income) 108.52% 60.04% 150.32% 139.65% 200.77% 123.42% 118.23% 118.57%
Dividend per Share 2 - - - - - - - -
Announcement Date 3/16/20 3/15/21 3/16/22 3/15/23 2/28/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 35.95 38.31 43.09 53.11 57.24 60.76 85.37 99.58 102.7 110.6 98.77 112.1 120.9 128.7 125.2
EBITDA 1 - - - - - - - - - - 49.83 60.81 56.12 54.42 -
EBIT 1 14 12.74 17.37 28.57 29.2 30.8 35.61 46.7 -37.19 41.69 32.6 44.47 49.59 52.45 47.57
Operating Margin 38.95% 33.26% 40.3% 53.79% 51.01% 50.7% 41.71% 46.9% -36.21% 37.71% 33% 39.66% 41.02% 40.75% 37.99%
Earnings before Tax (EBT) 1 14.07 12.81 17.46 28.24 26.01 33.01 37.31 48.51 -38.02 46.71 37 46.68 51.18 53.56 49.91
Net income 1 10.33 9.309 13.24 21.62 22.75 25.47 29.57 37.76 -30.76 34.84 26.12 34.39 37.9 38.55 37.35
Net margin 28.73% 24.3% 30.73% 40.7% 39.74% 41.92% 34.64% 37.92% -29.96% 31.51% 26.45% 30.67% 31.35% 29.95% 29.84%
EPS 2 0.1000 0.0900 0.1200 0.2000 0.2000 0.2200 0.2600 0.3300 -0.2900 0.2900 0.2121 0.2770 0.3078 0.3223 0.2833
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 11/9/21 3/16/22 5/10/22 8/9/22 11/9/22 3/15/23 5/10/23 8/9/23 11/8/23 2/28/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 94.5 140 191 298 138 461 686 -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 34.6 45 59.4 116 143 169 219 245
ROE (net income / shareholders' equity) 36.4% 44.2% 19.1% 32.8% 20.7% 46.8% 24% 19.5%
ROA (Net income/ Total Assets) 28.4% 39% 16.6% 27.1% 16.9% - - -
Assets 1 112.4 192.4 237.8 306.7 422.9 - - -
Book Value Per Share 0.8300 1.600 1.920 2.700 3.410 - - -
Cash Flow per Share 2 - - - - - 0.8700 1.340 -
Capex 1 0.02 0.01 1.02 0.03 0.23 0.06 0.16 0.17
Capex / Sales 0.02% 0.01% 0.72% 0.01% 0.06% 0.01% 0.03% 0.03%
Announcement Date 3/16/20 3/15/21 3/16/22 3/15/23 2/28/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Catalyst Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
14.89 USD
Average target price
26.71 USD
Spread / Average Target
+79.41%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
CATALYST PHARMACEUTICALS, INC. Stock Catalyst Pharmaceuticals, Inc.
-11.42% 1.76B
CSL LIMITED Stock CSL Limited
-4.66% 86.13B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+1.32% 39.82B
BIOGEN INC. Stock Biogen Inc.
-19.27% 30.42B
UCB Stock UCB
+57.86% 25.23B
INCYTE CORPORATION Stock Incyte Corporation
-17.69% 11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-43.00% 11.51B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-9.14% 11.95B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+5.24% 8.71B
INNOVENT BIOLOGICS, INC. Stock Innovent Biologics, Inc.
-8.42% 8.12B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. CPRX Stock
  4. Financials Catalyst Pharmaceuticals, Inc.